Physician profile
Jay M Fiore
NPI 1578708897
$4,519.80
in general payments reported to CMS, 2019-2025
26 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $321 · 2021: $442 · 2022: $619 · 2023: $839 · 2024: $934 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.78 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,197.96 | 2019-2025 | Clareon, Centurion, Ngenuity |
| Bausch & Lomb Americas INC. | $506.78 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Novartis Pharmaceuticals Corporation | $368.14 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $340.99 | 2019-2025 | Cequa, Xelpros |
| Astellas Pharma US INC | $230.64 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.08 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $214.96 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $210.44 | 2021-2025 | Tecnis Simplicity |
| Allergan, INC. | $184.21 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $164.22 | 2019-2021 | |
| Ivantis, INC | $143.70 | 2021 | |
| Abbvie INC. | $134.66 | 2022-2024 | |
| Oyster Point Pharma, INC. | $109.61 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $64.51 | 2019-2021 | |
| Shire North American Group INC | $58.03 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $56.97 | 2024-2025 | Dextenza |
| Dompe US, INC. | $45.71 | 2021-2024 | Oxervate |
| New World Medical,INC. | $44.49 | 2019-2022 | |
| Glaukos Corporation | $41.77 | 2019-2022 | |
| Thea Pharma INC. | $34.46 | 2024-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $32.23 | 2019-2021 | |
| Amgen INC. | $27.96 | 2024 | Tepezza |
| Rxsight INC | $25.09 | 2022 | |
| Horizon Therapeutics Plc | $24.03 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $18.76 | 2025 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.